Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targets-Reference-Cited by-同舟云学术

Ovarian cancer: Stat3, RhoA and IGF-IR as therapeutic targets

Published:2012-04 Issue:2 Volume:317 Page:207-217
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Gest Caroline,Mirshahi Pezhman,Li Hong,Pritchard Linda-Louise,Joimel Ulrich,Blot Emmanuel,Chidiac Jean,Poletto Bernard,Vannier Jean-Pierre,Varin Remi,Mirshahi Massoud,Cazin Lionel,Pujade-Lauraine Eric,Soria Jeannette,Soria Claudine

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference51 articles.

1. Cancer of the ovary;Cannistra;N. Engl. J. Med.,2004

2. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer;du Bois;J. Natl. Cancer Inst.,2003

3. Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer;Li;Mol. Cancer Res.,2008

4. Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells;Song;Biochem. J.,2007

5. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer;Obermair;Cancer Lett.,1999

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advance in vasculogenic mimicry in ovarian cancer (Review);Oncology Letters;2023-09-05

2. Immunotherapy checkpoints in ovarian cancer vasculogenic mimicry: Tumor immune microenvironments, and drugs;International Immunopharmacology;2022-10

3. Hormone-Glutamine Metabolism: A Critical Regulatory Axis in Endocrine-Related Cancers;International Journal of Molecular Sciences;2022-09-03

4. Loss of ZIP facilitates JAK2-STAT3 activation in tamoxifen-resistant breast cancer;Proceedings of the National Academy of Sciences;2020-06-12

5. Activation of STAT3 and STAT5 Signaling in Epithelial Ovarian Cancer Progression: Mechanism and Therapeutic Opportunity;Cancers;2019-12-19